Opgen inc   (OPGN)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $0.5844 $0.11 22.362%
Day's High: $0.5844 Week Perf: 25.95 %
Day's Low: $ 0.48 30 Day Perf: 72.49 %
Volume (M): 640 52 Wk High: $ 3.84
Volume (M$): $ 374 52 Wk Avg: $0.61
Open: $0.48 52 Wk Low: $0.17

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 9
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 1

Opgen Inc
OpGen Inc. is a biotechnology company that specializes in developing molecular testing and bioinformatics solutions for infectious diseases. The company was founded in 2001 and is headquartered in Gaithersburg, Maryland, United States.

OpGen's primary focus is on combating antibiotic resistance by providing tools for rapid and accurate identification of pathogens and their antibiotic resistance profiles. Their flagship product, Acuitas' Lighthouse, is a genomic surveillance solution that enables hospitals and labs to track and analyze bacterial genomes to better understand and respond to outbreaks.

In addition to Acuitas Lighthouse, OpGen also offers other products and services, including Acuitas' AMR Gene Panel tests for antibiotic resistance detection, Acuitas' Rapid Test kits for detecting pathogen DNA, and Acuitas' Resistome Test kits for comprehensive pathogen profiling.

The company's innovative technologies integrate molecular testing, bioinformatics, and data management to enable faster and more accurate identification of pathogens, leading to improved patient outcomes and more effective infection control practices.

OpGen Inc. collaborates with various healthcare institutions, pharmaceutical companies, and governmental organizations to further develop and validate their products. They have received several grants and awards for their contributions to the field of infectious disease diagnostics.

Overall, OpGen Inc. strives to advance the fight against antibiotic resistance by providing innovative molecular testing and bioinformatics solutions that help healthcare professionals make more informed treatment decisions.

   Company Address: 9717 Key West Avenue Rockville 20850 MD
   Company Phone Number: 813-1260   Stock Exchange / Ticker: NASDAQ OPGN
   OPGN is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Opgen Inc

OPGN's Remarkable Conduct Unveils Exciting Developments in Q3 2023

During the past 5 trading days, Opgen Inc's stock experienced a significant decrease of -16.27%. This dip brings the year-to-date performance to an impressive 184.36%. Currently, Opgen Inc's stock is trading on the NASDAQ at a value that is -39.6% below its 52-week average.
Recent financial reports from Opgen Inc show interesting developments. For the interval between July and September 30, 2023, OPGN's deficit has increased by $-0.46 per share when compared to the same period a year prior. On the other hand, the earnings per share have improved from $-0.93 per share in the preceding quarter. This indicates a mixed performance for the company's financial results.

Opgen Inc

OPGEN INC Faces Demand Quarter Struggles Throughout Fiscal Q2 2023

Opgen Inc, a leading player in the Medical Laboratories industry, has recently reported weak business performance for the quarter ending June 30, 2023. The company's losses have improved, but it still faces significant challenges that have led to a decline in revenue and an increase in the shortfall per share.
During the second quarter of 2023, Opgen Inc experienced a drop in revenue by -23.89%, with only $0.74 million generated compared to $0.97 million in the same period last year. This decline is concerning, especially considering that the overall industry witnessed a revenue gain during this time. The company's inability to capitalize on this industry growth raises questions about its competitive position and business strategy.

Opgen Inc

Opgen Inc Defies Odds with 94.455% Surge in Revenue Despite Challenging First Quarter

As a human, it seems that Opgen Inc, a precision medicine company focused on infectious diseases, has had a challenging fiscal first quarter of 2023. The company reported an increase in the deficit per share, going from $-0.15 to $-1.25 per share compared to the same time last year. Additionally, the deficit per share increased from $-0.23 in the prior quarter.
Despite these financial challenges, Opgen Inc saw a notable increase in revenue. The company's revenue grew by an impressive 94.455% to $0.91 million from $0.47 million in the corresponding quarter a year ago. Sequentially, Opgen Inc had an improvement in revenue of 26.581% from $0.72 million.


Opgen Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com